A rare complication of ulcerative colitis in children: Pyoderma gangrenosum

Piyoderma gangrenozum (PG), esas olarak ulserlerle karakterize nadir gorulen bir inflamatuar deri hastaligidir. PG’nin yarisindan fazlasi, inflamatuar bagirsak hastaligi gibi sistemik hastaliklarla iliskilidir. Olgularin yaklasik %4’u cocukluk doneminde gorulur. Burada ates ve kanli ishal ile basvuran, takip doneminde agrili bacak ulseri gelisen ve ulseratif kolit tanisi konulan 12 yasinda bir kiz hastayi sunuyoruz.

[1]  Xun-Tao Yin,et al.  Giant pyoderma gangrenosum in a patient with ulcerative colitis , 2020, Medicine.

[2]  E. Kechichian,et al.  Pediatric pyoderma gangrenosum: a systematic review and update , 2017, International journal of dermatology.

[3]  A. Kauzman,et al.  Oral Pyoderma Gangrenosum: Diagnosis, Treatment and Challenges: A Systematic Review , 2017, Head and Neck Pathology.

[4]  Sunil S Tholpady,et al.  Pediatric pyoderma gangrenosum: is it just big wounds on little adults? , 2016, The Journal of surgical research.

[5]  C. Zouboulis,et al.  Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab. , 2015, Journal of dermatological case reports.

[6]  T. Lobaton,et al.  Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease , 2013, Digestive Diseases and Sciences.

[7]  L. Eckhart,et al.  Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. , 2013, JAMA dermatology.

[8]  S. Ramamoorthy,et al.  Ustekinumab for Peristomal Pyoderma Gangrenosum , 2012, The American Journal of Gastroenterology.

[9]  S. Feldman,et al.  Pyoderma gangrenosum: a review and update on new therapies. , 2010, Journal of the American Academy of Dermatology.

[10]  G. Plewig,et al.  Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin‐1 receptor antagonist anakinra , 2009, The British journal of dermatology.

[11]  D. Han,et al.  Recombinant human epidermal growth factor enhances wound healing of pyoderma gangrenosum in a patient with ulcerative colitis. , 2008, Inflammatory bowel diseases.

[12]  R. Kirsner,et al.  Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series , 2007, International journal of dermatology.

[13]  U. Wollina.  Pyoderma gangrenosum – a review , 2007, Orphanet journal of rare diseases.

[14]  G. Dunnill,et al.  Diagnosis and treatment of pyoderma gangrenosum , 2006, BMJ : British Medical Journal.

[15]  M. Regueiro,et al.  Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[16]  C. Grin,et al.  Optimal Treatment of Pyoderma Gangrenosum , 2003, American journal of clinical dermatology.

[17]  M. Kodaira,et al.  Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine , 1998, Journal of Gastroenterology.

[18]  R. Powell,et al.  Pyoderma gangrenosum and its treatment , 1997, The Lancet.